Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes



Status:Terminated
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2013
End Date:March 2014

Use our guide to learn which trials are right for you!

A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes

The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin
compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment
Period.

The drug being tested in this study is called TAK-875. TAK-875 is being tested to treat
people who have type 2 diabetes. This study will look at glycemic control in people who take
TAK-875 in addition to metformin.

The study will enroll approximately 620 patients. Participants will be randomly assigned (by
chance, like flipping a coin) to one of the two treatment groups—which will remain
undisclosed to the patient and study doctor during the study (unless there is an urgent
medical need):

- TAK-875 50 mg

- Sitagliptin 100 mg

All participants will be asked to take one tablet at the same time each day throughout the
study. All participants will be asked to self-monitor their blood glucose levels and
document any increases in blood glucose or symptoms of hypoglycemia in a diary.

This multi-center trial will be conducted in the United States, Latin America, Europe and
Asia. The overall time to participate in this study is up to 42 weeks and participants will
make up to 15 visits to the clinic.

Due to potential concerns about liver safety, on balance, the benefits of treating patients
with fasiglifam (TAK-875) do not outweigh the potential risks.

For this reason, Takeda has decided voluntarily to terminate the development activities for
fasiglifam.

Inclusion Criteria:

1. In the opinion of the investigator, is capable of understanding and complying with
protocol requirements.

2. The participant or, when applicable, the participant's legally acceptable
representative signs and dates a written, informed consent form and any required
privacy authorization prior to the initiation of any study procedures.

3. Is male or female and 18 years of age or older with a historical diagnosis of type 2
diabetes mellitus (T2DM).

4. Meets one of the following criteria:.

1. Has an HbA1c ≥8% and <10.5%, and has been on a stable daily dose of ≥1500 mg (or
documented maximum tolerated dose (MTD)) of metformin for at least 8 weeks prior
to Screening. This participant will immediately enter the Placebo Run-in Period
according to Study Schedule A, or;

2. Has an HbA1c ≥8% and <10.5%, and has been on a stable daily dose of <1500 mg of
metformin without documented MTD for at least 8 weeks prior to Screening. After
completing the Screening Visit, these participants will have their metformin
dose immediately increased to ≥1500 mg (or MTD) for an 8- to 12-week
Titration/Stabilization Period according to Study Schedule B. Following stable
administration of metformin ≥1500 mg (or MTD) for 8 weeks, the participant must
qualify for entry into the Placebo Run-in Period by completing the Week -3
procedures and have an HbA1c ≥8% and <10.5%.

5. Has had no treatment with anti-diabetic agents other than metformin within 8 weeks
prior to Screening (Exception: if a participant has received other anti-diabetic
therapy for ≤7 days within the 8 weeks prior to Screening).

6. Has a body mass index (BMI) ≤45 kg/m^2 at Screening.

7. Participants regularly using other, non-excluded medications must be on a stable dose
and regimen for at least 4 weeks prior to Screening. However, as needed use of
prescription or over-the-counter medications is allowed at the discretion of the
investigator. Note: Participants who require initiation of a chronically administered
medication(s) due to a disease or condition diagnosed at Screening must be rescreened
after the new regimen has been stabilized.

8. A female participant of childbearing potential who is sexually active with a
non-sterilized male partner agrees to routinely use adequate contraception from
signing of the informed consent throughout the duration of the study and for 30 days
after the last dose of study drug.

9. Is able and willing to monitor glucose with a sponsor-provided home glucose monitor
and consistently record his or her own blood glucose concentrations in diaries.

Exclusion Criteria:

1. Has received any investigational compound within 30 days prior to Screening or has
received an investigational anti-diabetic drug within the 3 months prior to
Screening.

2. Has been randomized into a previous TAK-875 study.

3. Is an immediate family member, study site employee, or is in a dependent relationship
with a study site employee who is involved in conduct of this study (eg, spouse,
parent, child, or sibling) or may consent under duress.

4. Has donated or received any blood products within 12 weeks prior to Screening or is
planning to donate blood during the study.

5. Has a hemoglobin ≤12 g/dL (≤120 g/L) for males and ≤10 g/dL (≤100 g/L) for females at
Screening.

6. Has systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥95 mm Hg at
Screening Visit. (If the participant meets this exclusion criterion, the assessment
may be repeated once at least 30 minutes after the initial measurement and decision
will be made on the second measurement.)

7. Has history of cancer that has been in remission for <5 years prior to Screening. A
history of basal cell carcinoma or stage I squamous cell carcinoma of the skin is
allowed.

8. Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >2
x upper limit of normal (ULN) at Screening.

9. Has a total bilirubin level >ULN at Screening. Exception: if a participant has
documented Gilbert's Syndrome the participant will be allowed with an elevated
bilirubin level per the investigator's discretion.

10. Has serum creatinine ≥1.5mg/dL (≥133μmol/L) if male or ≥1.4 mg/dL (≥124 μmol/L) if
female and/or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m^2 at
Screening.

11. Has uncontrolled thyroid disease as determined by the investigator.

12. Has a history of laser treatment for proliferative diabetic retinopathy within 6
months prior to Screening.

13. Has a history of pancreatitis.

14. Has a history of gastric banding or gastric bypass surgery within one year prior to
Screening.

15. Has a known history of infection with human immunodeficiency virus (HIV), hepatitis B
virus (HBV), or hepatitis C virus (HCV).

16. Had coronary angioplasty, coronary stent placement, coronary bypass surgery,
myocardial infarction (MI), unstable angina pectoris, clinically significant abnormal
electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within
3 months prior to or at Screening.

17. Has a history of hypersensitivity, allergies, or has had an anaphylactic reaction(s)
to any component of TAK-875, metformin, or sitagliptin.

18. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol
abuse within 2 years prior to Screening.

19. Has received excluded medications prior to Screening or is expected to receive
excluded medications.

20. If female, is pregnant (confirmed by laboratory testing, ie, serum/urine human
chorionic gonadotropin (hCG), in females of childbearing potential) or lactating or
intending to become pregnant before, during, or within 1 month after participating in
this study; or intending to donate ova during such time period.

21. Is unable to understand verbal or written English or any other language for which a
certified translation of the approved informed consent is available.

22. Has any other physical or psychiatric disease or condition that in the judgment of
the investigator may affect life expectancy or may make it difficult to successfully
manage and follow the participant according to the protocol.
We found this trial at
45
sites
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Augusta, KS
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
?
mi
from
Carlisle, OH
Click here to add this to my saved trials
?
mi
from
Chandler, AZ
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Conyers, GA
Click here to add this to my saved trials
?
mi
from
Coronel Suarez,
Click here to add this to my saved trials
?
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Evans, GA
Click here to add this to my saved trials
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fort Mill, South Carolina 29707
?
mi
from
Fort Mill, SC
Click here to add this to my saved trials
?
mi
from
Fresno, CA
Click here to add this to my saved trials
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Hallandale Beach, Florida 33009
?
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
?
mi
from
Hickory, NC
Click here to add this to my saved trials
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
?
mi
from
Lakewood, CO
Click here to add this to my saved trials
?
mi
from
Laurens, SC
Click here to add this to my saved trials
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
?
mi
from
Medford, OR
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
?
mi
from
Modesto, CA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
North Miami, FL
Click here to add this to my saved trials
North Miami Beach, Florida 33162
?
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
?
mi
from
Odessa, TX
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Sanford, FL
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
?
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Thousand Oaks, California 91360
?
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
?
mi
from
Victoria, TX
Click here to add this to my saved trials